Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aristada in Schizophrenia and Schizoaffective Disorder (Deltoid vs Gluteal)
NCT02636842Phase 1Completed
- Sponsor
- Alkermes
- Start
- Dec 2015
- Primary completion
- Jun 2016
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aripiprazole lauroxil in schizophrenia and schizoaffective disorder (2 arms), sponsored by Alkermes. Primary endpoint: Maximum plasma concentration at 7 days. Started Dec 2015; status: completed.
02
Drugs
aripiprazole lauroxil
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT02636842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02636842.